BIOMAT Database Logo BIOMAT Database Logo

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. 2008

William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
Department of Microbiology and Immunology, University of Nevada School of Medicine, University of Nevada, Reno, NV 89557, USA.

Bortezomib is a proteasome inhibitor that has direct antitumor effects. We and others have previously demonstrated that bortezomib could also sensitize tumor cells to killing via the death ligand, TRAIL. NK cells represent a potent antitumor effector cell. Therefore, we investigated whether bortezomib could sensitize tumor cells to NK cell-mediated killing. Preincubation of tumor cells with bortezomib had no effect on short-term NK cell killing or purified granule killing assays. Using a 24-h lysis assay, increases in tumor killing was only observed using perforin-deficient NK cells, and this increased killing was found to be dependent on both TRAIL and FasL, correlating with an increase in tumor Fas and DR5 expression. Long-term tumor outgrowth assays allowed for the detection of this increased tumor killing by activated NK cells following bortezomib treatment of the tumor. In a tumor purging assay, in which tumor:bone marrow cell mixtures were placed into lethally irradiated mice, only treatment of these mixtures with a combination of NK cells with bortezomib resulted in significant tumor-free survival of the recipients. These results demonstrate that bortezomib treatment can sensitize tumor cells to cellular effector pathways. These results suggest that the combination of proteasome inhibition with immune therapy may result in increased antitumor efficacy.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D001897 Boronic Acids Inorganic or organic compounds that contain the basic structure RB(OH)2. Boronic Acid,Acid, Boronic,Acids, Boronic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic

Related Publications

William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
Inhibition of human NK cell-mediated killing by CD1 molecules.
June 2000, Journal of immunology (Baltimore, Md. : 1950),
William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
Functional visualization of NK cell-mediated killing of metastatic single tumor cells.
February 2022, eLife,
William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor.
July 2012, European journal of immunology,
William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
October 2013, International journal of cancer,
William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
Augmentation of NK cell-mediated cytotoxicity to tumor cells by inhibitory NK cell receptor blockers.
March 2004, International immunology,
William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
MHC class I molecules on adenovirus E1A-expressing tumor cells inhibit NK cell killing but not NK cell-mediated tumor rejection.
October 2001, International immunology,
William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
Inhibition of antibody-complement-mediated killing of tumor cells by hormones.
October 1976, Cancer research,
William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells.
January 2017, Frontiers in immunology,
William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents.
January 2003, Journal of cellular physiology,
William H D Hallett, and Erik Ames, and Milad Motarjemi, and Isabel Barao, and Anil Shanker, and David L Tamang, and Thomas J Sayers, and Dorothy Hudig, and William J Murphy
Selectively killing transformed cells through proteasome inhibition.
October 2009, Cell cycle (Georgetown, Tex.),
Copied contents to your clipboard!